Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines

Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt

“…The vaccine antigens were derived from N. meningitidis strains Mk499/03 [22], Mk222/02 [21] and BF2/97 [24,25]; all wild-type disease isolates from Ethiopia and Burkina Faso (Table 1). Three ST-181 MenX strains isolated in 2010: BuFa 9/10, BuFa 19/10, BuFa 24/10 and Ug 3/06, a ST-5403 MenX strain from Uganda in 2006 (Table 1) were used in serum bactericidal assays.…”

“…OMV were produced by extraction with deoxycholate buffer (Merck, Germany) and purified as previously described [22]. The AW-OMV vaccine formulation was prepared by combing the Aand W-OMV 1:1 to a total concentration of 100 g/ml OMV protein (lotMV23).…”

“…We have previously developed a combined MenA http://dx.doi.org/10.1016/j.vaccine.2014.09.063 0264-410X/© 2014 Elsevier Ltd. All rights reserved. and MenW vaccine for the meningitis belt based on OMV [21,22]. This AW-OMV vaccine was shown to be highly immunogenic in mice and induced higher or similar titers of functional antibodies against both MenA and MenW compared with licensed vaccines [22].…”

“…and MenW vaccine for the meningitis belt based on OMV [21,22]. This AW-OMV vaccine was shown to be highly immunogenic in mice and induced higher or similar titers of functional antibodies against both MenA and MenW compared with licensed vaccines [22]. The AW-OMV vaccine was tested in a clinical phase I trial in Cuba in 2013 (data analysis ongoing).…”

“…In the present study we have tested two trivalent AWX meningococcal vaccines in mice using the previously studied AW-OMV vaccine [22] combined with either X-OMV or X-PS [16]. X-OMV vaccines have also been shown to be immunogenic in mice, both alone and when combined with X-PS [16,23].…”